Published in Infect Immun on October 01, 2005
Subunit vaccine against the seven serotypes of botulism. Infect Immun (2007) 1.39
Analysis of epitope information related to Bacillus anthracis and Clostridium botulinum. Expert Rev Vaccines (2008) 1.13
Recombinant holotoxoid vaccine against botulism. Infect Immun (2007) 1.09
Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1. FEBS Lett (2010) 1.07
Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine. Vaccine (2007) 1.04
Llama single domain antibodies specific for the 7 botulinum neurotoxin serotypes as heptaplex immunoreagents. PLoS One (2010) 1.01
Recombinant botulinum neurotoxin A heavy chain-based delivery vehicles for neuronal cell targeting. Protein Eng Des Sel (2010) 0.94
In vitro detection and quantification of botulinum neurotoxin type e activity in avian blood. Appl Environ Microbiol (2011) 0.92
Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbits. PLoS One (2011) 0.91
Subunit vaccine efficacy against Botulinum neurotoxin subtypes. Vaccine (2011) 0.81
Recombinant rabies virus particles presenting botulinum neurotoxin antigens elicit a protective humoral response in vivo. Mol Ther Methods Clin Dev (2014) 0.78
Selection and characterization of a human monoclonal neutralizing antibody for Clostridium Botulinum neurotoxin serotype B. Bioorg Med Chem Lett (2008) 0.78
Epitope characterization of sero-specific monoclonal antibody to Clostridium botulinum neurotoxin type A. Hybridoma (Larchmt) (2011) 0.77
Epitope mapping of botulinum neurotoxins light chains. Toxicon (2012) 0.76
Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine. Clin Vaccine Immunol (2008) 0.76
Adenovirus F protein as a delivery vehicle for botulinum B. BMC Immunol (2010) 0.76
Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol (1998) 4.21
Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A (2002) 3.16
Mechanism of action of tetanus and botulinum neurotoxins. Mol Microbiol (1994) 3.04
Structure and function of tetanus and botulinum neurotoxins. Q Rev Biophys (1995) 2.57
Understanding the mode of action of diphtheria toxin: a perspective on progress during the 20th century. Toxicon (2001) 2.24
Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat Struct Biol (2003) 2.19
Neurotoxin gene clusters in Clostridium botulinum type A strains: sequence comparison and evolutionary implications. Curr Microbiol (2003) 1.83
Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J Cell Biol (2003) 1.81
Hypersensitivity reactions associated with botulinal antitoxin. Am J Med (1980) 1.74
Development of vaccines for prevention of botulism. Biochimie (2000) 1.73
Dose standardisation of botulinum toxin. Lancet (1990) 1.61
Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect Immun (1995) 1.61
The C-terminus of botulinum neurotoxin type A light chain contributes to solubility, catalysis, and stability. Protein Expr Purif (2004) 1.45
Presynaptic receptor arrays for clostridial neurotoxins. Trends Microbiol (2004) 1.42
Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect Immun (1998) 1.39
Human immune response to botulinum pentavalent (ABCDE) toxoid determined by a neutralization test and by an enzyme-linked immunosorbent assay. J Clin Microbiol (1988) 1.32
Nucleotide sequence and transcriptional analysis of the type A2 neurotoxin gene cluster in Clostridium botulinum. FEMS Microbiol Lett (2004) 1.25
Tetanus and botulism neurotoxins: a novel group of zinc-endopeptidases. Adv Exp Med Biol (1996) 1.14
Experience with the use of an investigational F(ab')2 heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt. Clin Infect Dis (1996) 1.14
Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies. FEBS Lett (2004) 1.07
Purification of Clostridium botulinum type A toxin. Biochim Biophys Acta (1970) 1.06
Purification of type E botulinum neurotoxin by high-performance ion exchange chromatography. Anal Biochem (1986) 1.04
Botulinum toxin: the story of its development for the treatment of human disease. Perspect Biol Med (1997) 0.98
Botulinum neurotoxins: mechanism of action and therapeutic applications. Mol Med Today (1996) 0.95
Management of botulism. Ann Pharmacother (2003) 0.93
Production and purification of the heavy chain fragment C of botulinum neurotoxin, serotype A, expressed in the methylotrophic yeast Pichia pastoris. Protein Expr Purif (2000) 0.89
Purification and characterization of alpha-toxin of Clostridium oedematiens type A. Jpn J Med Sci Biol (1983) 0.83
Protection strategies against botulinum toxin. Adv Exp Med Biol (1995) 0.82
[Botulism: the agent, mode of action of the botulinum neurotoxins, forms of acquisition, treatment and prevention]. C R Biol (2002) 0.79
Rapid SNP discovery and genetic mapping using sequenced RAD markers. PLoS One (2008) 13.64
Population genomics of parallel adaptation in threespine stickleback using sequenced RAD tags. PLoS Genet (2010) 7.05
The Group Health medical home at year two: cost savings, higher patient satisfaction, and less burnout for providers. Health Aff (Millwood) (2010) 6.60
Rapid and cost-effective polymorphism identification and genotyping using restriction site associated DNA (RAD) markers. Genome Res (2006) 5.80
Critical evaluation of two primers commonly used for amplification of bacterial 16S rRNA genes. Appl Environ Microbiol (2008) 4.58
SV2 is the protein receptor for botulinum neurotoxin A. Science (2006) 4.51
Construction and application for QTL analysis of a Restriction Site Associated DNA (RAD) linkage map in barley. BMC Genomics (2011) 3.42
Single-cell microbiology: tools, technologies, and applications. Microbiol Mol Biol Rev (2004) 2.53
RAD marker microarrays enable rapid mapping of zebrafish mutations. Genome Biol (2007) 2.07
Obesity during childhood and adolescence augments bone mass and bone dimensions. Am J Clin Nutr (2004) 2.00
Bacterial cytotoxins: targeting eukaryotic switches. Nat Rev Microbiol (2005) 1.98
Local de novo assembly of RAD paired-end contigs using short sequencing reads. PLoS One (2011) 1.98
Structural basis of cell surface receptor recognition by botulinum neurotoxin B. Nature (2006) 1.97
SNP discovery and genotyping for evolutionary genetics using RAD sequencing. Methods Mol Biol (2011) 1.96
Pasteurella multocida toxin activation of heterotrimeric G proteins by deamidation. Proc Natl Acad Sci U S A (2009) 1.88
An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. Proc Natl Acad Sci U S A (2007) 1.85
Neurotoxin gene clusters in Clostridium botulinum type A strains: sequence comparison and evolutionary implications. Curr Microbiol (2003) 1.83
Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J Cell Biol (2003) 1.81
Synthesis, characterization and development of a high-throughput methodology for the discovery of botulinum neurotoxin a inhibitors. J Comb Chem (2006) 1.79
High-density detection of restriction-site-associated DNA markers for rapid mapping of mutated loci in Neurospora. Genetics (2007) 1.78
Habitat degradation impacts black howler monkey (Alouatta pigra) gastrointestinal microbiomes. ISME J (2013) 1.66
Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Mol Biol Cell (2008) 1.66
Analysis of neurotoxin cluster genes in Clostridium botulinum strains producing botulinum neurotoxin serotype A subtypes. Appl Environ Microbiol (2008) 1.62
Pseudomonas aeruginosa ExoT ADP-ribosylates CT10 regulator of kinase (Crk) proteins. J Biol Chem (2003) 1.60
A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4. J Mol Biol (2006) 1.59
Unique substrate recognition by botulinum neurotoxins serotypes A and E. J Biol Chem (2006) 1.54
Phylogenetic analysis of Clostridium botulinum type A by multi-locus sequence typing. Microbiology (2008) 1.52
Plasmid encoded neurotoxin genes in Clostridium botulinum serotype A subtypes. Biochem Biophys Res Commun (2007) 1.52
Heterogeneity of vaginal microbial communities within individuals. J Clin Microbiol (2009) 1.50
Characterization of the fecal microbiome from non-human wild primates reveals species specific microbial communities. PLoS One (2010) 1.49
Sensitization of Staphylococcus aureus and Escherichia coli to antibiotics by the sesquiterpenoids nerolidol, farnesol, bisabolol, and apritone. Antimicrob Agents Chemother (2003) 1.47
The C-terminus of botulinum neurotoxin type A light chain contributes to solubility, catalysis, and stability. Protein Expr Purif (2004) 1.45
Genetic homogeneity of Clostridium botulinum type A1 strains with unique toxin gene clusters. Appl Environ Microbiol (2008) 1.44
Glycosylated SV2 and gangliosides as dual receptors for botulinum neurotoxin serotype F. Biochemistry (2009) 1.41
A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies. FEBS Lett (2007) 1.40
Using fluorescent sensors to detect botulinum neurotoxin activity in vitro and in living cells. Proc Natl Acad Sci U S A (2004) 1.40
Subunit vaccine against the seven serotypes of botulism. Infect Immun (2007) 1.39
Molecular mechanisms of the cytotoxicity of ADP-ribosylating toxins. Annu Rev Microbiol (2008) 1.35
In vivo rho GTPase-activating protein activity of Pseudomonas aeruginosa cytotoxin ExoS. Infect Immun (2002) 1.35
Regulation of neurotoxin complex expression in Clostridium botulinum strains 62A, Hall A-hyper, and NCTC 2916. Anaerobe (2004) 1.30
Mechanism of substrate recognition by botulinum neurotoxin serotype A. J Biol Chem (2007) 1.30
Bleeding stomal varices: case series and systematic review of the literature. Clin Gastroenterol Hepatol (2008) 1.29
Protein kinase D links Gq-coupled receptors to cAMP response element-binding protein (CREB)-Ser133 phosphorylation in the heart. J Biol Chem (2008) 1.29
Safety of using a computerized rounding and sign-out system to reduce resident duty hours. Acad Med (2010) 1.29
Identification of a lycopene beta-cyclase required for bacteriorhodopsin biogenesis in the archaeon Halobacterium salinarum. J Bacteriol (2002) 1.28
Bimodal modulation of the botulinum neurotoxin protein-conducting channel. Proc Natl Acad Sci U S A (2009) 1.26
Nucleotide sequence and transcriptional analysis of the type A2 neurotoxin gene cluster in Clostridium botulinum. FEMS Microbiol Lett (2004) 1.25
Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors. PLoS Pathog (2011) 1.24
Comparative genomics of Gardnerella vaginalis strains reveals substantial differences in metabolic and virulence potential. PLoS One (2010) 1.24
Comparison of the primary rat spinal cord cell (RSC) assay and the mouse bioassay for botulinum neurotoxin type A potency determination. J Pharmacol Toxicol Methods (2010) 1.21
Novel application of human neurons derived from induced pluripotent stem cells for highly sensitive botulinum neurotoxin detection. Toxicol Sci (2012) 1.21
Pasteurella multocida: from zoonosis to cellular microbiology. Clin Microbiol Rev (2013) 1.21
Characterization of Clostridium botulinum strains associated with an infant botulism case in the United Kingdom. J Clin Microbiol (2005) 1.18
Intracellular localization modulates targeting of ExoS, a type III cytotoxin, to eukaryotic signalling proteins. Mol Microbiol (2002) 1.17
Effects of purification on the bioavailability of botulinum neurotoxin type A. Toxicology (2008) 1.16
Auto-ADP-ribosylation of Pseudomonas aeruginosa ExoS. J Biol Chem (2002) 1.16
Secular trends in colon and rectal cancer relative survival. J Natl Cancer Inst (2013) 1.16
SV2 mediates entry of tetanus neurotoxin into central neurons. PLoS Pathog (2010) 1.15
Spreading a medical home redesign: effects on emergency department use and hospital admissions. Ann Fam Med (2013) 1.15
Mechanism of botulinum neurotoxin B and G entry into hippocampal neurons. J Cell Biol (2007) 1.15
A survey of new temperature-sensitive, embryonic-lethal mutations in C. elegans: 24 alleles of thirteen genes. PLoS One (2011) 1.15
Botulinum neurotoxin A protease: discovery of natural product exosite inhibitors. J Am Chem Soc (2010) 1.14
Association of botulinum neurotoxin serotypes a and B with synaptic vesicle protein complexes. Biochemistry (2007) 1.14
Intracellular membrane localization of pseudomonas ExoS and Yersinia YopE in mammalian cells. J Biol Chem (2003) 1.14
Infection with Mycobacterium bovis BCG diverts traffic of myelin oligodendroglial glycoprotein autoantigen-specific T cells away from the central nervous system and ameliorates experimental autoimmune encephalomyelitis. Clin Diagn Lab Immunol (2003) 1.13
Discovery and structural characterization of a small molecule 14-3-3 protein-protein interaction inhibitor. Proc Natl Acad Sci U S A (2011) 1.12
Gangliosides as high affinity receptors for tetanus neurotoxin. J Biol Chem (2009) 1.12
Amyloidosis presenting as lower gastrointestinal hemorrhage. WMJ (2008) 1.11
Substrate recognition of VAMP-2 by botulinum neurotoxin B and tetanus neurotoxin. J Biol Chem (2008) 1.11
Multiple pocket recognition of SNAP25 by botulinum neurotoxin serotype E. J Biol Chem (2007) 1.10
A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region. J Mol Biol (2010) 1.10
Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro. Infect Immun (2013) 1.10